Read by QxMD icon Read


Shin-Ya Tamechika, Kaneshige Sasaki, Yoshihito Hayami, Shin-Ichiro Ohmura, Shinji Maeda, Shiho Iwagaitsu, Taio Naniwa
The randomized, clinical trial demonstrated that switching to monthly minodronate from weekly alendronate and risedronate provides greater increases in patients' satisfaction and bone mineral density and more substantial decreases in a bone resorption marker than continuing weekly alendronate and risedronate in patients with systemic rheumatic diseases on glucocorticoid therapy. PURPOSE: Osteoporosis and associated fractures are major concerns for patients with systemic rheumatic diseases on long-term glucocorticoid therapy...
June 13, 2018: Archives of Osteoporosis
Takashi Teramoto, Takeshi Kamiya, Taira Sakurai, Fuminori Kanaya
BACKGROUND AND OBJECTIVE: Computational homology is an emerging mathematical tool for characterizing shapes of data. In this work, we present a methodology using computational homology for obtaining quantitative measurements of the connectivity in bone morphometry. We introduce the Betti number ratios as novel morphological descriptor for the classification of bone fine structures in three dimensions. METHODS: A total of 51 Japanese white rabbits were used to investigate the connectivity of bone trabeculae after the administration of alendronate in a tendon graft model in rabbits...
August 2018: Computer Methods and Programs in Biomedicine
Tianxiang Geng, Xi Chen, Mengxue Zheng, Haochen Yu, Shuai Zhang, Shouxuan Sun, Haohui Guo, Qunhua Jin
Aseptic loosening and menopause‑induced osteoporosis are caused by an imbalance between bone formation and osteolysis. With an aging population, the probability of simultaneous occurrence of such conditions in an elderly individual is increasing. Strontium ranelate (SR) is an anti‑osteoporosis drug that promotes bone formation and inhibits osteolysis. The present study compared the effects of SR with those of the traditional anti‑osteoporosis drug alendronate (ALN) using an ovariectomized mouse model of osteolysis...
June 5, 2018: Molecular Medicine Reports
Elisa Martín-Merino, Amaia Calderón-Larrañaga, Samuel Hawley, Beatriz Poblador-Plou, Ana Llorente-García, Irene Petersen, Daniel Prieto-Alhambra
Background: Missing data are often an issue in electronic medical records (EMRs) research. However, there are many ways that people deal with missing data in drug safety studies. Aim: To compare the risk estimates resulting from different strategies for the handling of missing data in the study of venous thromboembolism (VTE) risk associated with antiosteoporotic medications (AOM). Methods: New users of AOM (alendronic acid, other bisphosphonates, strontium ranelate, selective estrogen receptor modulators, teriparatide, or denosumab) aged ≥50 years during 1998-2014 were identified in two Spanish (the Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria [BIFAP] and EpiChron cohort) and one UK (Clinical Practice Research Datalink [CPRD]) EMR...
2018: Clinical Epidemiology
Erkki Soini, Ossi Riekkinen, Heikki Kröger, Petri Mankinen, Taru Hallinen, Janne P Karjalainen
Purpose: Osteoporosis is asymptomatic morbidity of the elderly which develops slowly over several years. Osteoporosis diagnosis has typically involved Fracture Risk Assessment (FRAX) followed by dual energy X-ray absorptiometry (DXA) in specialist care. Point-of-care pulse-echo ultrasound (PEUS) was developed to overcome DXA-related access issues and to enable faster fracture prevention treatment (FPT) initiation. The objective of this study was to evaluate the cost-effectiveness of two proposed osteoporosis management (POMs: FRAX→PEUS-if-needed→DXA-if-needed→FPT-if-needed) pathways including PEUS compared with the current osteoporosis management (FRAX→DXA-if-needed→FPT-if-needed)...
2018: ClinicoEconomics and Outcomes Research: CEOR
Daniel Wolverton, David P Elliott
OBJECTIVE: To review clinical trial data supporting the use of drugs to treat osteoporosis in the oldest adults, 74 years of age and older. DATA SOURCES: The PubMed database (September 1969-June 2017) was searched utilizing the following Medical Subject Headings terms: osteoporosis, postmenopausal, aged, 80 and over, and fractures, bone, in combination with diphosphonates, denosumab, parathyroid hormone, raloxifene, and calcitonin. STUDY SELECTION/DATA EXTRACTION: An initial search revealed 119 results, of which 18 clinical trials were included...
June 1, 2018: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
Francisco Javier Manzano-Moreno, Javier Ramos-Torrecillas, Elvira de Luna-Bertos, Rebeca Illescas-Montes, Timothy R Arnett, Concepción Ruiz, Olga García-Martínez
OBJECTIVES: The objectives of this study were to analyze the effect of pH on the growth and activity of osteoclasts treated with different doses of two nitrogen-containing BPs, zoledronate and alendronate. MATERIALS AND METHODS: Murine osteoclasts cultured on dentine disks were treated with zoledronate (50 or 500 nM) or alendronate (500 or 5 μM) at two different pH values (7.4 or 7.0). Osteoclasts were counted with transmitted light microscopy, apoptosis/necrosis was studied with flow cytometry and confocal microscopy, and resorption pit number and depth were calculated using reflected light and scanning electron microscopy...
June 6, 2018: Clinical Oral Investigations
Olivier Lamy, Elena Gonzalez Rodriguez, Delphine Stoll, Bérengère Aubry-Rozier, Françoise Livio
Multiple Vertebral Fractures after Denosumab Discontinuation: How to Avoid Them? Abstract. Denosumab is a monoclonal antibody raised against the RANK ligand that inhibits the maturation and activity of osteoclasts. It decreases bone resorption, increases bone density and reduces fracture risk. However, after its discontinuation, a significant rebound effect appears that lasts about two years. It results in increased markers of bone remodeling, a loss of bone density that may be greater than gain, and an increased risk of multiple vertebral fractures...
June 2018: Praxis
Somying Patntirapong, Mahatana Poolgesorn
BACKGROUND: A serious adverse effect of long-term bisphosphonate (BP) administration is bisphosphonate-related osteonecrosis of the jaw (BRONJ). Among different proposed pathogenesis, suppression of immune cells is gaining interest. Because monocytes/macrophages could get access to BP since residing in the blood and bone microenvironment, the aim of this study was to analyze the behaviors of macrophages after bisphosphonate treatments in vitro. METHODS: THP-1 cell, an established human monocytic cell model, was used in this study...
June 5, 2018: Oral Diseases
Risa B Burns, Harold Rosen, Sarah Berry, Gerald W Smetana
Osteoporosis is a skeletal disorder characterized by reduced bone strength that increases the risk for fracture. Approximately 10 million men and women in the United States have osteoporosis, and more than 2 million osteoporosis-related fractures occur annually. In 2016, the American Association of Clinical Endocrinologists issued the "Clinical Practice Guideline for the Diagnosis and Treatment of Postmenopausal Osteoporosis," and in 2017, the American College of Physicians issued the guideline "Treatment of Low Bone Density or Osteoporosis to Prevent Fracture in Men and Women...
June 5, 2018: Annals of Internal Medicine
Athanasios N Tsartsalis, George I Lambrou, Dimitrios Tsartsalis, Christos Savvidis, Maria Karantza, Evangelos Terpos, Christina Kanaka-Gantenbein, George P Chrousos, Antonis Kattamis
Thalassemia Major (TM) is a clinical entity with a high prevalence of low bone mass. The aim of the present study was to perform a meta-analysis of all available data on the role of bisphosphonates (BPs) in the therapy of thalassemia major-induced osteoporosis. The PRISMA recommendations for reporting systematic reviews and meta-analyses were used to guide the present study. We searched PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) through March 31, 2017 for articles related to thalassemia and BPs...
May 2, 2018: Hormones: International Journal of Endocrinology and Metabolism
Babita Madan, Mitchell J McDonald, Gabrielle E Foxa, Cassandra R Diegel, Bart O Williams, David M Virshup
Dysregulated Wnt signaling is associated with the pathogenesis of cancers, fibrosis, and vascular diseases. Inhibition of Wnt signaling has shown efficacy in various pre-clinical models of these disorders. One of the key challenges in developing targeted anti-cancer drugs is to balance efficacy with on-target toxicity. Given the crucial role Wnts play in the differentiation of osteoblasts and osteoclasts, acute inhibition of Wnt signaling is likely to affect bone homeostasis. In this study, we evaluated the skeletal effect of small molecule inhibitor of an o-acyl transferase porcupine (PORCN) that prevents Wnt signaling by blocking the secretion of all Wnts...
2018: Bone Research
Evren Gundogdu, Meliha Ekinci, Emre Ozgenc, Derya Ilem Ozdemir, Makbule Asikoglu
OBJECTIVE: The purpose of this study was to develop lipid-water based drug delivery system of Alendronate Sodium (ALD) in liquid and solid form obtained by using spray drying method and compare these two forms with radioactive cell culture studies. METHODS: This study included that development of liquid and solid form obtained by spray drying method, radiolabelling of ALD with 99mTc, preparation of formulations containing 99mTc -ALD and evaluation of their permeability with Caco-2 cell...
May 28, 2018: Current Radiopharmaceuticals
Chia-Yu Su, Hsiu-O Ho, Ying-Chen Chen, Yu-Ting Yu, Der-Zen Liu, Fang-Ching Chao, Ming-Thau Sheu
Complex hydrogels formed with chitosan (CS) and ring-opened polyvinyl pyrrolidone (roPVP) as a swellable mucoadhesive gastroretentive drug dosage form (smGRDDF) were prepared and characterized. CS/roPVP hydrogels were produced by blending CS with roPVP obtained by basic treatment of PVP. Effects of the heating time and NaOH concentration employed for preparing roPVP, and CS molecular weights (Mws), and roPVP/CS ratios on the swelling ability of the resultant hydrogels were characterized. Rheological characteristics were further examined...
May 25, 2018: Scientific Reports
Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli, Robin K Dore, John P Bilezikian, Kenneth G Saag
Purpose: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). Methods: Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 months of ALN. We evaluated the incidence of vertebral and nonvertebral fractures and changes in BMD over the entire 43-month period from ACTIVE baseline to the end of ACTIVExtend and for the 24-month extension only...
May 24, 2018: Journal of Clinical Endocrinology and Metabolism
Zhuliang Gu, Peiling Liang, Shaodong Xie
OBJECTIVE: To compare the efficacy differences between catgut implantation at stellate ganglion combined with oral administration of alendronate sodium and oral administration of alendronate sodium alone on postmenopausal osteoporosis (PO). METHODS: Sixty patients of PO were randomly divided into an observation group and a control group, 30 cases in each one. The patients in the control group were treated with oral administration of alendronate sodium. Based on the treatment of control group, the patients in the observation group were treated with catgut implantation at stellate ganglion...
May 12, 2018: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
Young-Seok Lee, Rishab Gupta, Jeong-Taik Kwon, Dae-Chul Cho, Ye Jin Seo, Sung Young Seu, Eui Kyun Park, Inbo Han, Chi-Heon Kim, Joo-Kyung Sung, Kyoung-Tae Kim
BACKGROUND CONTEXT: Diabetes and menopause can cause severe osteoporosis. In general, menopause and diabetes can lead to an imbalance in bone turnover, which results in secondary osteoporosis. However, the efficacy of antiresorptive drugs against this form of osteoporosis has not been extensively evaluated. OBJECTIVE: The aim of this study was to determine the changes in vertebral bone remodeling when postmenopausal osteoporosis is accompanied by diabetes and the efficacy of bisphosphonates and selective estrogen-receptor modulators (SERMs) against these outcomes...
May 21, 2018: Spine Journal: Official Journal of the North American Spine Society
Kaili Wang, Chunjing Guo, Xue Dong, Yueming Yu, Bingjie Wang, Wanhui Liu, Daquan Chen
Many cancers such as human breast cancer and lung cancer easily metastasize to bones, leading to the formation of secondary tumors in advanced stage. Based on the CD44-targeted effect of oHA and bone-targeted effect of ALN, we prepared a reduction-responsive, CD44 receptor-targeting and bone-targeting nano-micelle, called CUR-loaded ALN-oHA-S-S-CUR micelles. In this study, we aimed to evaluate the antitumor activity and bone-targeting ability of CUR-loaded ALN-oHA-S-S-CUR micelles. The in vivo experiment results showed that a larger number of micelles was gathered in the bone metastatic tumor tissue and reduced the bone destruction...
May 24, 2018: Molecular Pharmaceutics
Abhishek Sahu, Youngmin Hwang, Cristian Vilos, Jong-Min Lim, Sunghyun Kim, Won Il Choi, Giyoong Tae
The calcium (Ca2+) ion concentration in the blood serum is tightly regulated, and any abnormalities in the level of serum calcium ions are associated with many potentially dangerous diseases. Thus, monitoring of the Ca2+ ion concentration in the blood serum is of fundamental importance. Gold nanoparticle (GNP)-based colorimetric biosensors have enormous potential in clinical diagnostic applications due to their simplicity, versatility, and unique optical properties. In this study, we have developed an alendronate functionalized gold nanoparticle (GNP-ALD) system for the measurement of Ca2+ ion concentration in biological samples...
May 22, 2018: Nanoscale
Jinlei Dong, Hnin Ei Thu, Mohammed A S Abourehab, Zahid Hussain
Osteoporosis is a medical condition of fragile bones with an increased susceptibility to bone fracture. Despite having availability of a wide range of pharmacological agents, prevalence of this metabolic disorder is continuously escalating. Owing to excellent biomedical achievements of nanomedicines in the last few decades, we aimed combo delivery of bone anti-resorptive agent, alendronate (ALN), and bone density enhancing drug, curcumin (CUR), in the form of polymeric nanoparticles. To further optimize the therapeutic efficacy, the prepared ALN/CUR nanoparticles were decorated with hyaluronic acid which is a well-documented biomacromolecule having exceptional bone regenerating potential...
May 18, 2018: International Journal of Biological Macromolecules
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"